The company’s board of directors appointed John Rakow, uBiome’s general counsel, as interim CEO and confirmed that a special committee will be overseeing an independent internal investigation.
“We intend to cooperate fully with government authorities and private payors to satisfactorily resolve the questions that have been raised, and we will take any corrective actions that are needed to ensure we can become a stronger company better able to serve patients and healthcare providers,” Mr. Rakow said in a statement.
UBiome offers three at-home tests that use genetic sequencing to derive a clinical report from a patient’s gut, vaginal or nasal microbiome. On April 26, the FBI conducted a raid of the company’s headquarters, stemming from allegations that uBiome hires physicians to order their tests without patient approval and bills government programs, such as the private Medicare Advantage plan, for tests.
More articles about health IT:
Hancock Regional Hospital CEO details ransomware attack
Why Microsoft is saying goodbye to passwords
Rapper Pitbull looks to biotech for next investment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.